These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 12180294

  • 21. Consensus conference. Treatment of hepatitis C.
    Agence Nationale d'Accréditation et d'Evaluation en Santé (ANAES).
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B303-20. PubMed ID: 12180305
    [Abstract] [Full Text] [Related]

  • 22. [Treatment of chronic hepatitis C and alcohol consumption].
    Mathurin P, Canva V, Dharancy S, Paris JC.
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B248-51. PubMed ID: 12180297
    [No Abstract] [Full Text] [Related]

  • 23. [Alternative measures for patients with chronic hepatitis C unresponsive to interferon therapy].
    Imazeki F.
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):540-3. PubMed ID: 15359858
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
    El-Zayadi AR, Attia M, Badran HM, El-Tawil A, Zalata K, Barakat E, Selim O, El-Nakeeb A, Saied A.
    Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Evaluating the efficacy of interferon therapy on hepatitis C patients].
    Shiraha H, Iwasaki Y, Shiratori Y.
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):489-92. PubMed ID: 15359847
    [No Abstract] [Full Text] [Related]

  • 31. A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia.
    Hayashi J, Furusyo N, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S.
    J Infect Dis; 2000 May; 181(5):1523-7. PubMed ID: 10823749
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [What therapy is meaningful in chronic hepatitis C and resection of hepatocellular carcinoma for recurrence prophylaxis?].
    Malfertheiner P.
    Dtsch Med Wochenschr; 2002 Nov 29; 127(48):2580. PubMed ID: 12457331
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
    Bressler BL, Guindi M, Tomlinson G, Heathcote J.
    Hepatology; 2003 Sep 29; 38(3):639-44. PubMed ID: 12939590
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.
    Fujita N, Kaito M, Kai M, Sugimoto R, Tanaka H, Horiike S, Konishi M, Iwasa M, Watanabe S, Adachi Y.
    J Viral Hepat; 2006 Jul 29; 13(7):441-8. PubMed ID: 16792537
    [Abstract] [Full Text] [Related]

  • 38. Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone.
    Calanca LN, Fehr T, Jochum W, Fischer-Vetter J, Müllhaupt B, Wüthrich RP, Ambühl PM.
    J Clin Virol; 2007 May 29; 39(1):54-8. PubMed ID: 17409018
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Relationship between infection with hepatitis C virus and hepatocellular carcinoma in Japan.
    Iino S.
    Antivir Ther; 1998 May 29; 3(Suppl 3):143-6. PubMed ID: 10726064
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.